Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoir
- Author
- WESTBY, Mike1 ; LEWIS, Marilyn1 ; WHITCOMB, Jeannette2 ; YOULE, Mike3 ; POZNIAK, Anton L4 ; JAMES, Ian T1 ; JENKINS, Tim M1 ; PERROS, Manos1 ; VAN DER RYST, Elna1
[1] Pfizer Global Research and Development, Sandwich, United Kingdom
[2] Monogram Biosciences, South San Francisco, California, United States
[3] Royal Free Hospital, London, United Kingdom
[4] Chelsea and Westminster Hospital, London, United Kingdom - Source
Journal of virology. 2006, Vol 80, Num 10, pp 4909-4920, 12 p ; ref : 39 ref
- ISSN
- 0022-538X
- Scientific domain
- Biochemistry, molecular biology, biophysics; Microbiology, infectious diseases; Virology
- Publisher
- American Society for Microbiology, Washington, DC
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Maladie émergente Maraviroc Microbiologie Récepteur chimiokine CCR5 Récepteur chimiokine CXCR4 Réservoir SIDA Traitement Virologie Virus HIV1 Epidémiologie Immunodéficit Immunopathologie Infection Lentivirus Retroviridae Virose Virus immunodéficience humaine Virus
- Keyword (en)
- Emerging disease Maraviroc Microbiology CCR5 chemokine receptor CXCR4 chemokine receptor Reservoir AIDS Treatment Virology HIV-1 virus Epidemiology Immune deficiency Immunopathology Infection Lentivirus Retroviridae Viral disease Human immunodeficiency virus Virus
- Keyword (es)
- Enfermedad emergente Maraviroc Microbiología Receptor quimioquina CCR5 Receptor quimioquina CXCR4 Depósito SIDA Tratamiento Virología HIV-1 virus Epidemiología Inmunodeficiencia Inmunopatología Infección Lentivirus Retroviridae Virosis Human immunodeficiency virus Virus
- Classification
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A05 Microbiology / 002A05C Virology / 002A05C06 Epidemiology
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A05 Microbiology / 002A05C Virology / 002A05C10 Miscellaneous
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02D Viral diseases of the lymphoid tissue and the blood. Aids
- Discipline
- Infectious pathology Microbiology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17752170
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1128/JVI.80.10.4909-4920.2006 
https://dx.doi.org/10.1128/JVI.80.10.4909-4920.2006
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1128\/JVI.80.10.4909-4920.2006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:224:\"Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoir\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Journal of virology\";s:9:\"\u0000*\u0000stitle\";s:8:\"J. virol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"80\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"4909\";s:8:\"\u0000*\u0000epage\";s:4:\"4920\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-538X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WESTBY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mike\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"LEWIS, Marilyn\";i:1;s:19:\"WHITCOMB, Jeannette\";i:2;s:11:\"YOULE, Mike\";i:3;s:16:\"POZNIAK, Anton L\";i:4;s:12:\"JAMES, Ian T\";i:5;s:14:\"JENKINS, Tim M\";i:6;s:13:\"PERROS, Manos\";i:7;s:18:\"VAN DER RYST, Elna\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:224:\"Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoir\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:33:\"American Society for Microbiology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1128\/JVI.80.10.4909-4920.2006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:224:\"Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoir\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Journal of virology\";s:9:\"\u0000*\u0000stitle\";s:8:\"J. virol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"80\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"4909\";s:8:\"\u0000*\u0000epage\";s:4:\"4920\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-538X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WESTBY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mike\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"LEWIS, Marilyn\";i:1;s:19:\"WHITCOMB, Jeannette\";i:2;s:11:\"YOULE, Mike\";i:3;s:16:\"POZNIAK, Anton L\";i:4;s:12:\"JAMES, Ian T\";i:5;s:14:\"JENKINS, Tim M\";i:6;s:13:\"PERROS, Manos\";i:7;s:18:\"VAN DER RYST, Elna\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:224:\"Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoir\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:33:\"American Society for Microbiology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.1128\/JVI.80.10.4909-4920.2006\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1128\/JVI.80.10.4909-4920.2006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:224:\"Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoir\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Journal of virology\";s:9:\"\u0000*\u0000stitle\";s:8:\"J. virol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"80\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"4909\";s:8:\"\u0000*\u0000epage\";s:4:\"4920\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-538X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WESTBY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mike\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"LEWIS, Marilyn\";i:1;s:19:\"WHITCOMB, Jeannette\";i:2;s:11:\"YOULE, Mike\";i:3;s:16:\"POZNIAK, Anton L\";i:4;s:12:\"JAMES, Ian T\";i:5;s:14:\"JENKINS, Tim M\";i:6;s:13:\"PERROS, Manos\";i:7;s:18:\"VAN DER RYST, Elna\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:224:\"Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoir\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:33:\"American Society for Microbiology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1128\/JVI.80.10.4909-4920.2006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:224:\"Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoir\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Journal of virology\";s:9:\"\u0000*\u0000stitle\";s:8:\"J. virol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"80\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"4909\";s:8:\"\u0000*\u0000epage\";s:4:\"4920\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-538X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WESTBY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mike\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"LEWIS, Marilyn\";i:1;s:19:\"WHITCOMB, Jeannette\";i:2;s:11:\"YOULE, Mike\";i:3;s:16:\"POZNIAK, Anton L\";i:4;s:12:\"JAMES, Ian T\";i:5;s:14:\"JENKINS, Tim M\";i:6;s:13:\"PERROS, Manos\";i:7;s:18:\"VAN DER RYST, Elna\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:224:\"Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoir\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:33:\"American Society for Microbiology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1128\/JVI.80.10.4909-4920.2006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:224:\"Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoir\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Journal of virology\";s:9:\"\u0000*\u0000stitle\";s:8:\"J. virol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"80\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"4909\";s:8:\"\u0000*\u0000epage\";s:4:\"4920\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-538X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WESTBY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mike\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"LEWIS, Marilyn\";i:1;s:19:\"WHITCOMB, Jeannette\";i:2;s:11:\"YOULE, Mike\";i:3;s:16:\"POZNIAK, Anton L\";i:4;s:12:\"JAMES, Ian T\";i:5;s:14:\"JENKINS, Tim M\";i:6;s:13:\"PERROS, Manos\";i:7;s:18:\"VAN DER RYST, Elna\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:224:\"Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoir\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:33:\"American Society for Microbiology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
